[New Product] Completion of Development and Launch of TPO Alternative Peptide(TPOR agonist)
2024/03/21
We have successfully developed a peptide that demonstrates high affinity and agonist activity against TPOR (Thrombopoietin receptor), similar to TPO (Thrombopoietin). Starting from March 2024, we will start selling the TPO Alternative Peptide (TPOR Agonist) under the product code "PG-010".
PG-010 is intended to be used in the field of regenerative medicine and cell therapy for the proliferation and maturation of megakaryocytes, induction of differentiation from pluripotent stem cells to hematopoietic stem cells, and manufacturing of allogeneic cell therapy products, such as CAR-T.
We can provide the free sample. Please feel free to contact us from [Contact].
